Poolbeg Pharma Plc – Placing to raise £3.5 million, Executive Chair Cathal Friel subscribes for £250,000
Poolbeg Pharma Plc (AIM: POLB), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, is pleased to announce that it has raised £3.5 million (before expenses) pursuant to a placing of 58,333,328 new ordinary shares of 0.02 pence each in the capital of the Company (“Placing Shares”) with certain existing institutional and other investors (“Placing”). The Placing will be at the issue price of 6 pence per new Ordinary Share (“Issue Price”).
